Michael Charles Ryan - Net Worth and Insider Trading

Michael Charles Ryan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael Charles Ryan owns 1 companies in total, including Kiromic BioPharma Inc (KRBP) .

Click here to see the complete history of Michael Charles Ryan’s form 4 insider trades.

Insider Ownership Summary of Michael Charles Ryan

Ticker Comapny Transaction Date Type of Owner
KRBP Kiromic BioPharma Inc 2021-07-01 Chief Technology Officer

Michael Charles Ryan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Michael Charles Ryan Ownership Network

Ownership Network List of Michael Charles Ryan

No Data

Ownership Network Relation of Michael Charles Ryan


Michael Charles Ryan Owned Company Details

What does Kiromic BioPharma Inc do?

Who are the key executives at Kiromic BioPharma Inc?

Michael Charles Ryan is the Chief Technology Officer of Kiromic BioPharma Inc. Other key executives at Kiromic BioPharma Inc include CFO Brian Hungerford , Interim CFO Daniel Grant Clark , and director & Chairman & CEO & and President Internati Maurizio Chiriva .

Kiromic BioPharma Inc (KRBP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kiromic BioPharma Inc (KRBP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kiromic BioPharma Inc (KRBP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kiromic BioPharma Inc (KRBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Kiromic BioPharma Inc Insider Transactions

No Available Data

Michael Charles Ryan Mailing Address

Above is the net worth, insider trading, and ownership report for Michael Charles Ryan. You might contact Michael Charles Ryan via mailing address: 7707 Fannin, Suite 140, Houston Tx 77054.

Discussions on Michael Charles Ryan

No discussions yet.